FEATURED EDITORIAL
We caught up with Minutia CEO Katy Digovich to discuss engineered iPSC-derived islets intended for transplantation into the forearm, which could make a functional cure for insulin-dependent diabetes broadly accessible.
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- Organizing Digital Systems Around Novel Modalities
- The Future Is Ancient: Evolution, Metabolics, And AI
- The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future
- Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire
- Aligning Standards, Validation, And Governance For Digital Preclinical Research
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
FEATURED APPLICATION CONTENT
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Anova And Nouveau Biosciences Announce Partnership To Deliver Clinical Trials Of Kromastat For The Treatment Of Relapsed Or Refractory Cutaneous And Peripheral T-Cell Lymphoma
- CellCarta Launches Digital Pathology And AI Consortium To Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
- Kelun-Biotech And Harbour BioMed Announce NMPA Approval Of IND Application For SKB575/HBM7575 For The Treatment Of Asthma
- Insilico Medicine And Bora Pharmaceuticals Announce Strategic Alliance For AI-Driven Drug Discovery And Development
- Lynk Pharmaceuticals Announces Completion Of Patient Enrollment In Phase III Clinical Trial Of Zemprocitinib For Ankylosing Spondylitis
- Atrium Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ATR 1072 For Treatment Of PRKAG2 Syndrome
- HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102, A Novel Oral NLRP3 Inhibitor For Cardiovascular Risk Reduction
- Atea Pharmaceuticals Initiates First-In-Human Phase 1 Clinical Trial Of AT-587 For The Treatment Of Hepatitis E Virus
- Apnimed Announces FDA Acceptance Of New Drug Application For AD109, An Investigational Oral Pill To Treat Adults With Obstructive Sleep Apnea (OSA)
- Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation And European Medicines Agency Orphan Medicinal Product Designation (OMPD) For NB4168 For The Treatment Of Ataxia Telangiectasia (A-T)
ARCHIVED NEWSLETTER
- 07.15.26 -- Human-Centric Models For Modern Drug Development
- 07.14.26 -- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- 07.07.26 -- Discovery Dialogues: Winston Haynes, VP, Computational Sciences And Engineering, LabGenius Tx
- 07.03.26 -- Drug Discovery Online Best Of June
- 06.30.26 -- A New De Novo Protein Design Platform For GPCR Drug Discovery
